Key points are not available for this paper at this time.
In patients with giant-cell arteritis, upadacitinib at a dose of 15 mg - but not 7.5 mg - with a 26-week glucocorticoid taper showed efficacy superior to that of placebo with a 52-week glucocorticoid taper. (Funded by AbbVie; SELECT-GCA ClinicalTrials.gov number, NCT03725202.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Daniël Blockmans
Universitair Ziekenhuis Leuven
S. Penn
Arathi R. Setty
New England Journal of Medicine
University of Pennsylvania
KU Leuven
McMaster University
Building similarity graph...
Analyzing shared references across papers
Loading...
Blockmans et al. (Wed,) studied this question.
synapsesocial.com/papers/69d850c0f4e559c61eae36dc — DOI: https://doi.org/10.1056/nejmoa2413449